Thyroid receptor ligands. Part 2: Thyromimetics with improved selectivity for the thyroid hormone receptor beta.
Hangeland, J.J., Doweyko, A.M., Dejneka, T., Friends, T.J., Devasthale, P., Mellstrom, K., Sandberg, J., Grynfarb, M., Sack, J.S., Einspahr, H., Farnegardh, M., Husman, B., Ljunggren, J., Koehler, K., Sheppard, C., Malm, J., Ryono, D.E.(2004) Bioorg Med Chem Lett 14: 3549-3553
- PubMed: 15177471
- DOI: https://doi.org/10.1016/j.bmcl.2004.04.032
- Primary Citation of Related Structures:
1R6G - PubMed Abstract:
A set of thyromimetics having improved selectivity for TR-beta1 were prepared by replacing the 3'-isopropyl group of 2 and 3 with substituents having increased steric bulk. From this limited SAR study, the most potent and selective compounds identified were derived from 2 and contained a 3'-phenyl moiety bearing small hydrophobic groups meta to the biphenyl link. X-ray crystal data of 15c complexed with TR-beta1 LBD shows methionine 442 to be displaced by the bulky R3' phenyl ethyl amide side chain. Movement of this amino acid side chain provides an expanded pocket for the bulky side chain while the ligand-receptor complex retains full agonist activity.
Organizational Affiliation:
Pharmaceutical Research Institute, Bristol-Myers Squibb, Princeton, NJ 08543, USA. jon.hangeland@bms.com